The need for a regional CRO that is able to contribute to international clinical development programs both in terms of recruitment and quality, whilst simultaneously offering the benefits of Latin America for aspects such as cost and timelines, is clear. Continued consolidation in the industry by global CROs has made this need more apparent and even more acute. By working with large global CROs, with inflexible one-size-fits-all procedures, global blended rates and disregard of local/regional idiosyncrasies, drug development companies are not able to fully unlock the tremendous potential that Latin America can offer.